In a groundbreaking move for women’s health, the name polycystic ovary syndrome (PCOS) is set to be replaced by polyendocrine metabolic ovarian syndrome (PMOS). This change, regarded as one of the most extensive global engagement processes related to a medical condition’s nomenclature, aims to enhance understanding, diagnosis, and treatment of a disorder that affects millions of women worldwide.
The Need for Change
For years, the term PCOS has been a source of confusion and misrepresentation. Traditionally, the name suggested an increase in ovarian cysts, which is misleading. Instead, the condition is characterised by the presence of immature ovarian follicles, resulting from hormonal imbalances. This misnomer has led to widespread misunderstanding, underdiagnosis, and inadequate treatment for those affected.
A representative from Monash University in Australia, who played a crucial role in the name change, highlighted how the previous designation has hindered recognition of the disorder’s complexity. “The inaccurate name has negatively influenced awareness, education, and even the level of research, attention and funding it has received,” stated the chair of the UK charity Verity, who has lived with PMOS for nearly two decades.
What the Name Change Represents
The switch to PMOS underscores the broader hormonal and metabolic disturbances linked to the condition, which encompasses issues with insulin, androgens, and neuroendocrine and ovarian hormones. As Professor Helena Teede, who spearheaded the international name change team, articulated: “PMOS is building on what we knew before but really is reflective of the much more diverse and broad features of this condition.”
This new terminology aims to dismantle the stigma often associated with PMOS, particularly around weight gain and mental health challenges. Women with PMOS frequently experience anxiety, depression, and increased risk of metabolic disorders, including Type 2 diabetes. Robyn Vettese, chair of the PMOS Patient Advisory Council, expressed hope that the rebranding will lead to better recognition of patients’ diverse symptoms and promote long-term health support.
A Unifying Movement
The transition from PCOS to PMOS has been described as an unprecedented global initiative. Over a decade of advocacy culminated in a survey revealing that 85.6% of patients and 76.1% of healthcare professionals supported the name change. This broad consensus was achieved through the collaboration of over 22,000 individuals, alongside the contributions of 56 key academic, clinical, and patient organisations.
As the name change journey unfolds, it sets a precedent for incorporating patient voices into healthcare discussions. This inclusive approach is paramount for tailoring treatments and improving the overall care landscape for those impacted by PMOS.
Future Directions for PMOS Advocacy
Looking to the future, Vettese sees this rebranding as a catalyst for healthcare providers to deepen their understanding of PMOS and promote a holistic approach to women’s health. Dr. Jamie Benham, an endocrinologist involved in the initiative, shares a vision for increasing awareness about the implications of the name change while fostering collaboration with patients to ensure that research aligns with their needs.
Recent findings from the 2024 McKinsey Health Institute report, “Closing the Women’s Health Gap,” emphasise the critical need for improved diagnosis and funding for PMOS research. As we move through the three-year transition period, there is optimism that Canadian healthcare professionals across various fields—including endocrinology, gynaecology, and dermatology—will enhance PMOS care.
Why it Matters
The rebranding of PCOS to PMOS is more than just a change in terminology; it represents a significant leap towards better understanding and management of a complex condition that affects millions. By shedding light on the multifaceted nature of PMOS, this initiative promises to enhance awareness, improve diagnosis, and ensure that women receive the comprehensive care they deserve. As healthcare systems evolve, the hope is that this change will lead to a future where women with PMOS are recognised, understood, and supported throughout their lives.
